This site uses cookies to improve your experience and to provide services and advertising. By continuing to browse, you agree to the use of cookies described in our Cookies Policy. You may change your settings at any time but this may impact on the functionality of the site. To learn more see our Cookies Policy.
OK
#Open journalism No news is bad news

Your contributions will help us continue to deliver the stories that are important to you

Support The Journal
Dublin: 15 °C Monday 3 August, 2020
Advertisement

Major buyout by Dublin-based firm Actavis will create 'blockbuster' pharma player

The deal with Botox maker Allergan is worth a cool €53 billion.

Image: Damian Dovarganes/AP/Press Association Images

DUBLIN-HEADQUARTERED FIRM Actavis plans to buy out Botox maker Allergan to create one of the world’s biggest pharmaceuticals companies.

Actavis announced it would pay about $66 billion (€53 billion) in cash and shares for the rival pharma company, which also has significant operations in Ireland.

The tie-up would create one of the world’s top-10 pharmaceutical outfits by sales turnover, expected to hit a combined $23 billion (€18.5 billion) next year alone.

Actavis, which has its administrative base in the US, said the deal would mean its operations spanned everything from neuroscience to plastic surgery.

Chief executive Brent Saunders said: ”We will establish an unrivaled foundation for long-term growth, anchored by leading, world-class blockbuster franchises and a premier late-stage pipeline that will accelerate our commitment to build an exceptional, sustainable portfolio.”

#Open journalism No news is bad news Support The Journal

Your contributions will help us continue to deliver the stories that are important to you

Support us now

Botox-maker in demand

Allergan runs its main European support office out of Dublin and employs nearly 800 staff in its factory at Westport, Co Mayo.

It previously fended off a $60 billion takeover bid from Canadian firm Valeant and was also flagged for a possible merger with another Dublin-headquartered company, Shire.

The boards of both Actavis and Allergan have given their tick of approval to the deal, although shareholders for the two companies still have to give their approval.

READ: US pharma giant’s €43 billion deal with Ireland-based firm could be off the table now >

READ: Multinationals were worth less to the Irish economy last year as the Viagra effect wore off >

  • Share on Facebook
  • Email this article
  •  

About the author:

Peter Bodkin  / Editor, Fora

Read next:

COMMENTS (6)